LAG3 CRISPR/Cas9 Lentivirus (Integrating)

Catalog #
78053
$795 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T-cells, Natural Killer cells, B-cells, and plasmacytoid dendritic cells. Its main ligand is the MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T-cells in a similar fashion as CTLA-4 and PD-1, and has been reported to play a role in T-reg suppressive function. A number of LAG3 antibodies are in preclinical development for the treatment of cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1, because antibodies targeting CTLA-4 or PD-1 only activate effector T-cells while failing to inhibit T-reg activity, whereas an antagonist LAG3 antibody can both activate effector T-cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) T-reg suppressive activity.

The LAG3 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1A promoter, along with 4 sgRNA (single guide RNA) targeting human LAG3 (GenBank Accession #NM_002286) driven by a U6 promoter (Figures 1 and 2).

The integrating lentivirus integrates randomly into the cell’s genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest.

 Schematic of the Lenti-vector used to generate the LAG3 CRISPR/Cas9 Lentivirus.

Figure 1. Schematic of the Lenti-vector used to generate the LAG3 CRISPR/Cas9 Lentivirus.

 

Gene Target: Primer ID: sgRNA Sequence
LAG3 LAG3-1 GTTCCGGAACCAATGCACAG
LAG3 LAG3-2 GGGAGTTACCCAGAACAGTG
LAG3 LAG3-3 CGTCCCGCCCCACATACTCG
LAG3 LAG3-4 GCTCACATCCTCTAGTCGAA

Figure 2. List of sgRNA Sequences in the LAG3 CRISPR/Cas9 Lentivirus.

 

Synonyms
Lymphocyte-activation gene 3 CRISPR, CD223 Lentivirus
Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 μl x 2) of lentivirus at a titer ≥1 x 106 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Formulation

The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.